Shenyang Xingqi Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 300573.SZ

Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2023: USD 1.66

Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue Per Share is USD 1.66 for the year ending December 31, 2023, a 13.77% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2022 was USD 1.46, a 11.38% change year over year.
Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2021 was USD 1.31, a 40.48% change year over year.
Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2020 was USD 0.93, a 34.25% change year over year.
Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2019 was USD 0.70, a -10.88% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shenzhen Stock Exchange: 300573.SZ

Shenyang Xingqi Pharmaceutical Co.,Ltd

CEO	Ms. E. Gao
IPO Date	Dec. 9, 2016
Location	China
Headquarters	No. 68, Lishui Street
Employees	1,995
Sector	Health Care
Industries Pharmaceuticals Cosmetics Eyewear

Description

Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.

Key trends

Past 5 years